Cisplatin Induces Up-Regulation of KAI1, a Metastasis Suppressor Gene, in MCF-7 Breast Cancer Cell Line
Purpose: To investigate the effect of cisplatin on cell toxicity and metastasis through modulation of KAI1 gene expression.
Methods: MCF-7cells were incubated with different concentrations of cisplatin for 24 h. RNA was extracted by trizol and cDNA synthesized. KAI1 and TBP were chosen as target and internal control genes, respectively. Specific primers were designed by primer express software, v.3.0. KAI1/TBP and gene expression ratio was calculated using the formula, 2 -ΔΔCt.
Results: Cisplatin exerted a dose-dependent inhibitory effect on the viability of highly metastatic MCF-7 cells. KAI1/TBP gene expression ratios were 1.97 ± 0.19 (p < 0.05), 2.96 ± 0.55 (p < 0.05), 9.06 ± 0.27 (p < 0.001) and 12.38 ± 0.88 (p < 0.01) in 10, 20, 50 and 100 μM concentrations of cisplatin. Conclusion: These findings indicate that cisplatin can inhibit metastasis by up-regulating KAI1 gene in MCF-7cells.
Keywords: Cisplatin; KAI1; Metastasis; Breast Cancer; Real-time PCR.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.